Pluristem Therapeutics to Present at Upcoming Industry Conferences
HAIFA, Israel, May 5, 2011
Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (DAX:PJT) (TASE:PLTR), announced today that over the next two months, company executives will be presenting at four leading industry events. The presentations follow the completion of six-month follow-up on patients treated with the Company's Critical Limb Ischemia therapeutic, PLX-PAD.
"As part of our ongoing clinical, scientific and financial progress, we are pleased to be invited to present at a variety of financial and scientific conferences," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "These presentations will enable us to discuss the competitive advantages of our platform, as well as our planned product portfolio, with a number of strategic target audiences."
Phase I clinical trials suggest that Pluristem's placenta-derived cell therapy, PLX-PAD, is safe, improves quality of life, and is potentially effective in treating patients and reducing amputation rate in those suffering from Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD). Among the 27 patients treated with PLX-PAD, no mortality events and only one amputation were recorded, representing a 3.7% amputation rate. This represents a 75% reduction in amputation rate compared to historical data, which varies between 20-40%.
Over the next two months, Pluristem will be presenting at the following conferences:
* Oppenheimer 12th Annual Israeli Conference
May 15, 2011, Tel-Aviv, Israel
Zami Aberman, Chairman & CEO, will participate in a
Q&A Session with Oppenheimer's Analyst
2:30 -- 3:30 pm, Hall #3
* 17th Annual Meeting of the International Society
for Cellular Therapy
May 18-21, Rotterdam, The Netherlands
Frida Grynspan, PhD, VP Research and Development,
will present:
"Commercialization strategies for the development
of PLX-PAD; Placental
expanded adherent stromal cells, an "off the shelf"
product"
Saturday, May 21 from 1:15 to 2:45 pm
* BioMed Israel 2011
May 23-25, Tel Aviv, Israel
Zami Aberman, Chairman& CEO, will present:
"Placental Derived Adherent Stromal Cells for the
Treatment of Critical Limb
Ischemia and Heart Diastolic Dysfunction"
Company Presentations
Monday, May 23 between 12:55 - 1:35 pm, Hall D
Company Presentations, Biopharma
Tuesday, May 24 from 5:10pm to 5:30 pm, Hall B
* 2011 Bio International Convention - June 27-30,
Washington, DC.
Zami Aberman, Chairman & CEO, will participate in
the Israel delegation and
will present at the Israel Pavilion - Booth 3737,
Hall A
* The 2011 AOSSM Annual Meeting -- July 7-10, San
Diego, California.
Dr. William R. Prather, Sr. VP Corporate
Development, will participate in the
event and meet with interested parties at the
Company's booth in the exhibition area. |
